China:Antibody levels and immune memory 23 years after hepatitis B vaccination

StephenW

Vaccine. 2011 Jan 27. [Epub ahead of print]

Antibody levels and immune memory 23 years after primary plasma-derived
hepatitis B vaccination: Results of a randomized placebo-controlled trial cohort
from China where endemicity is high.

Wu Q, Zhuang GH, Wang XL, Wang LR, Li N, Zhang M.
Department of Epidemiology and Biostatistics, Xi'an Jiaotong University College
of Medicine, Xi'an, Shaanxi 710061, PR China.

Abstract
The duration of protection of hepatitis B vaccine remains incompletely
understood. To assess the long-term protection provided by a primary vaccine
series, the current study again recruited all subjects of a previous randomized
placebo-controlled trial cohort 23 years after vaccination. Two hundred and
sixty-one healthy children aged 5-9 years living in a highly HBV-endemic country
were enrolled in the primary trial and received three doses of plasma-derived
vaccine or placebo. The primary placebo receivers who did not receive any
immunization against hepatitis B were used as non-vaccinated controls in the
current study. After eliminating the interference of an early booster dose and
vaccines outside the study, 48.1% (39/81) vaccinees still maintained anti-HBs
titers ≥10mIU/mL at Year 23, higher than 34.7% (26/75) in non-vaccinated
controls (P=0.088). 75-100% of vaccinees with anti-HBs titer <10mIU/mL at Year
23 in different sub-groups divided according to early immune backgrounds
developed a rapid and robust antibody anamnestic response after a booster dose,
highly significantly different from non-vaccinated controls who received the
same dose of vaccine (7.5%, P<0.01). No case of clinically significant HBV
infection was found in the primary cohort during the whole 23 years, but 10
transient HBsAg seroconversions in the primary placebo group and one in the
primary vaccine group were determined. Anti-HBc positive rate obviously tended
to be lower in vaccinees compared with non-vaccinated controls at Year 23. These
results suggest a persisting immune memory and certain protection for 23 years
after primary vaccination in children living in highly HBV-endemic areas.
Clinically insignificant infections, which cannot be avoided and may often occur
in vaccinees, play a positive role in the maintaining of immunity to HBV.
Booster doses should be unnecessary for more than 20 years after a full primary
immunization in children (as catch-up vaccination) and, also likely, in newborns
living in highly HBV-endemic areas.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PMID: 21277403 [PubMed - as supplied by publisher]
疫苗的研制。 2011年1月27日。 [EPUB的提前打印]

抗体水平和免疫记忆23年后的主要血源
乙肝疫苗：一项随机安慰剂对照试验结果队列
其中从中国流行高。

吴强，庄生长激素，王希林，王LR的，李宁，张米
流行病学和生物统计学系，西安交通大学
医学院，西安，陕西710061，中国公关。

摘要
对乙肝疫苗的保护期尚未完全
理解。为了评估长期保护提供了一个主要疫苗
系列，目前的研究再次征聘的所有科目上一个随机
安慰剂对照试验接种后23年队列。两百
六十一岁儿童5-9岁的健康，以高度乙肝流行国家生活
已报名参加初级试验，并获得三个血源性剂量
疫苗或安慰剂。接收器的主要安慰剂谁没有收到任何
对乙肝疫苗被用作未接种疫苗控制在
目前的研究。在排除了早期干预和加强剂
疫苗的研究外，48.1％（八十一分之三十九）接种疫苗仍维持抗- HBs
滴度≥10mIU/mL在23年，高于34.7％的未接种疫苗（75分之26）
对照组（P = 0.088）。 75-100％，与抗- HBs滴度<接种者在新年10mIU/mL
在不同的子群分为23根据早期免疫背景
开发了一种快速和强大的抗体后，回忆应答增强剂，
极显着不同，未接种疫苗控制谁收到了
同等剂量的疫苗（7.5％，磷“0.01）。无临床显着乙肝病毒病例
感染被发现在主队列在整个23年，但10
短暂的乙肝表面抗原seroconversions在主安慰剂组和一
原疫苗组进行了测定。抗- HBc阳性率明显趋向
将与在23年未接种对照组相比，接种较低。这些
结果表明了坚持免疫记忆和一定的保护23年
乙肝病毒后，在高流行地区的儿童主要接种。
临床上微不足道的感染，不能避免，可能经常发生
在疫苗接种，起到对HBV的免疫力维持积极的作用。
加强剂量应为20年以上后，完整的小学不必要
免疫接种的儿童（如追赶疫苗），并也有可能，在新生儿
生活在乙肝高流行地区。

版权所有© 2011爱思唯尔版权所有。

结论：21277403 [PubMed的 - 由出版商提供]




(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc